跳转至内容
Merck
CN

5.08194

Sigma-Aldrich

HDAC6 Inhibitor III

别名:

HDAC6 Inhibitor III

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C20H19N3O3
化学文摘社编号:
分子量:
349.38
UNSPSC代码:
12352200
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

方案

≥98% (HPLC)

质量水平

表单

powder

效能

29 nM IC50

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

cream

溶解性

DMSO: 10 mg/mL

储存温度

−20°C

一般描述

A cell-permeable, quinazolin-4-one based hydroxamic acid containing compound that acts as a potent and selective inhibitor of histone deacetylase 6 (HDAC6; IC50 = 29 nM). Exhibits high selectivity over other HDACs (IC50 = 1.88, 6.45, 1.75, and 4.08 µM for HDAC1, 2, 8, and 11, respectively). Does not affect hERG activity (>10 µM) or p450 activity (IC50 >6.5 µM). Blocks b-amyloid (Ab) aggregation in the presence of zinc (IC50 = 9.5 µM) and improves learning-based performance in mice. Induces neurite outgrowth (EC50 = 7.3 and 9.2 µM in PC12 and SH-SY5Y cells, respectively) and enhances synaptic activity (EC50 = 6.5 and 6.8 µM in PC12 and SH-SY5Y cells, respectively). Shown to enhance acetylated a-tubulin levels in hippocampus region of mice with Ab lesions.

Please note that the molecular weight for this compound is batch-specific due to variable water content.

生化/生理作用

Cell permeable: yes
Reversible: yes

包装

Packaged under inert gas

其他说明

Yu, C.W., et al. 2013. J. Med. Chem.56, 6775.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

Toxicity: Standard Handling (A)

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持